U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597070) titled 'Universal Immunization to Fortify Immunotherapy Efficacy and Response' on May 12.
Brief Summary: Although immune checkpoint inhibitors (ICIs) have substantially extended survival in many patients, most patients do not achieve durable responses on these treatments. There is a substantial unmet need for methods to sensitize more patients to ICIs. Studies have shown that personalized mRNA lipid nanoparticle vaccines enhance antitumor immunity in combination with PD1 inhibition, under the assumption that these vaccines generate T cells reactive against the targets encoded by the mRNA in the vaccines. However, it was recently found that m...